Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, Tony; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz; Cho, Byoung; Turna, Hande; Castro, Gilberto; Srimuninnimit, Vichien; Laktionov, Konstantin; Bondarenko, Igor; Kubota, Kaoru; Lubiniecki, Gregory; Zhang, Jin; Kush, Debra; Lopes, Gilberto

doi:10.1016/s0140-6736(18)32409-7

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Atıf İçin Kopyala

Mok T. S. K., Wu Y., Kudaba I., Kowalski D. M., Cho B. C., Turna H. Z., ...Daha Fazla

LANCET, cilt.393, sa.10183, ss.1819-1830, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 393 Sayı: 10183
Basım Tarihi: 2019
Doi Numarası: 10.1016/s0140-6736(18)32409-7
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1819-1830
İstanbul Üniversitesi Adresli: Evet

Özet

Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.